First Manhattan
ACOR

First Manhattan’s Acorda Therapeutics ACOR Stock Holding History

First Manhattan’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$39 – 1402
2024
Q1 		$39 Hold
3
– – ﹤0.01% 1399
2023
Q4 		$45 Hold
3
– – ﹤0.01% 1424
2023
Q3 		$44 Hold
3
– – ﹤0.01% 1474
2023
Q2 		$39 Hold
3
– – ﹤0.01% 1412
2023
Q1 		$29 Hold
3
– – ﹤0.01% 1505
2022
Q4 		$38 Hold
3
– – ﹤0.01% 1661
2022
Q3 		$0 Hold
3
– – ﹤0.01% 1705
2022
Q2 		$0 Hold
3
– – ﹤0.01% 1710
2022
Q1 		$0 Hold
3
– – ﹤0.01% 1726
2021
Q4 		$0 Hold
3
– – ﹤0.01% 1719
2021
Q3 		$0 Hold
3
– – ﹤0.01% 1713
2021
Q2 		$0 Hold
3
– – ﹤0.01% 1649
2021
Q1 		$0 Buy
+3
New +$369 ﹤0.01% 1583

Other funds holding ACOR

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

First Manhattan's ACOR Position: Q2 2024 in Review

First Manhattan sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 3 shares — an estimated $39 sold.

First Manhattan first reported a position in ACOR in Q1 2021 and held it in 13 quarters. The position peaked at $45 in Q4 2023. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • First Manhattan reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • First Manhattan sold 3 Acorda Therapeutics shares in Q2 2024, an estimated $39.
  • First Manhattan first reported a position in Acorda Therapeutics in Q1 2021 and held it in 13 quarters.
  • First Manhattan's Acorda Therapeutics position peaked at $45 in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.